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The purification of animal insulin preparations and the use of human recombinant insulin have markedly reduced the incidence but not 
completely suppressed the occurrence of insulin allergy manifestations. Advances in technologies concerning the mode of delivery of 
insulin, i.e. continuous subcutaneous insulin infusion (CSII), and the use of insulin analogues, resulting from the alteration in the amino 
acid sequence of the native insulin molecule, may influence the immunogenicity and antigenicity of native insulin. Instead of increasing 
allergy reactions, CSII has been reported to represent a successful alternative treatment in diabetic patients presenting local or generalized 
allergy to insulin or other components (zinc, protamine) of conventional treatment. Most recent reports concern CSII-treated patients using  
short-acting insulin analogues (essentially insulin lispro), although the precise role of these insulin analogues remains unclear as allergy to 
 1
them has also been described. Finally, data on antigenicity and immunogenicity of long-acting insulin analogues (glargine, detemir), which 
may mimic the basal insulin delivery with CSII, remain scarce at present time. 
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Introduction 
Continuous subcutaneous insulin infusion (CSII), also called insulin pump therapy, was introduced in the 1970s and was proven to 
be superior on multiple daily insulin injections in a recent meta-analysis of 12 randomised controlled trials comparing the two treatment 
modalities [2]. Recent data showed that CSII with short-acting insulin analogues (insulin lispro, insulin aspart) provides better control of 
postprandial hyperglycaemia and further reduced risk of hypoglycaemia, leading to a significant improvement in glycated haemoglobin 
(HbA1c) and quality of life [3,4]. Therefore, short-acting insulin analogues are now considered as the first choice for CSII therapy [5,6].  In 
addition, this approach may offer new possibilities in the management of allergy to human insulin. 
Soon after the introduction of insulin in the 1920s, clinicians became aware of the immunological complications and skin manifestations 
that result from reaction to its therapeutic use [7]. Animal (beef, pork) insulins are foreign proteins and have been implicated as allergens, 
with a much higher skin reactions to beef insulin than to porcine insulin. In addition, noninsulin components of insulin preparations may 
also react as allergens, such as various impurities (“dirty insulin”), preservatives (metacresol) or agents to prolong action (zinc, protamine) 
[8,9].  Primary allergy to recombinant human insulin has also been described, although the prevalence of hypersensitivity reactions (mostly 
localised to the injection site and more exceptionally generalised) has dramatically decreased from as many as 50-60 % in the 1950-1960s 
[10,11] to less than 1-3 % in the late 1990s [12-15]. However, the current prevalence of such insulin allergy reactions is not precisely 
known among the diabetic population. 
Whereas clinical allergy has become a less-frequent observation, new modalities of insulin delivery may magnify its propensity. For 
instance, continued use of subcutaneous insulin-infusion pumps raises the important issue of stability of insulin within the delivery system 
as insulin aggregates may promote insulin hypersensitivity reactions [16]. Furthermore, insulin analogues, resulting from a modified 
sequence of amino acids of recombinant human insulin, may present new epitopes for recognition by the immune system and thus 
potentially alter the antigenicity and immunogenicity of insulin in diabetic patients [17-19]. However, as previously suggested [16], the 
development of physically stable insulin monomers (thus reducing the risk of insulin aggregates) may further decrease the clinical 
incidence of cutaneous insulin allergy as compared to human regular insulin and minimize the complications associated with insulin-
infusion therapy. Interestingly, insulin desensitisation with CSII delivering insulin lispro has been reported in several diabetic patients, 
suggesting that the insulin pump and short-acting insulin may be useful as an alternative treatment in insulin allergy [20].  
The present review aims at describing the effects of CSII and/or short-acting insulin analogues (lispro, aspart) on insulin allergy, i.e. 
localized and more exceptionally generalized manifestations related to insulin hypersensitivity. As new long-acting insulin analogues 
(glargine, detemir) are able to provide a better basal insulin delivery as compared to NPH insulin and thus may be considered as an 
alternative to CSII [21,22], recent, albeit scarce, data concerning allergy reactions to these analogues or attempts of insulin desensitization 
with them will be also briefly summarized. 
 
1. Hypersensitivity to insulin : brief overview 
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Insulin injected into the subcutaneous tissue of diabetic patients can elicit various reactions from the immune system (Figure 1) 
[9,23,24]. Although the frequency of insulin allergy has been reduced with the present availability of high purification technology and with 
the use of human insulin, reactions varying in severity from mild discomfort to life-threatening still occur in 0.1 to 3.0 % of patients 
receiving human insulin [13,15,25,26]. Three types of allergic reactions to human insulin have been described [14,27]. Type I immediate 
hypersensitivity reactions is by far the commonest. This is an IgE dependent reaction that is mediated by the release of vaso-active 
substances mainly from basophiles and mast cells. Symptoms start at the site of injection with swelling, erythema and itching, and may 
progress to a generalised reaction, ranging in severity from simple urticaria to anaphylaxis. Symptoms usually resolve after one hour. The 
reactions typically occur one week after initiation of therapy and in patients who have restarted insulin treatment after a therapeutic gap. 
Sometimes, biphasic reactions occur, with an initial wheal-flare reaction, followed by a late-phase peaking at 4-6 hours and lasting usually 
less than 24 hours. However, induration at the injection site may last longer, occasionally several days. These delayed reactions are IgG-
mediated and cell-mediated, characterized by a local mononuclear infiltration. Type III hypersensitivity (Arthus type) represents local 
insulin-antibody complex reactions that result in complement fixation and leukocyte attraction with resultant inflammatory response. This 
serum sickness type is very rare with insulin and is mediated by IgG antibodies. Skin reactions involve small, localized subdermal, 
tenderness and painful non-erythematous nodules with central hematomas at injection sites, occurring around 6-8 hours after the insulin 
injection and lasting for 48 hours [28]. Type IV reaction corresponds to tuberculin-like T lymphocyte-mediated delayed hypersensitivity. 
The cutaneous nodules could be distinguished from those of the type III hypersensitivity reactions as they occur usually 24 hours or more 
after the insulin injection, lasting for 4-7 days. 
Confirmation of the allergic nature of skin lesions (which might also be due to incorrect injection technique) can be obtained by 
intradermal testing using a 1 :10 dilution of the insulin preparation [26]. Appearance of a lesion within 60 minutes of injection indicates 
immediate hypersensitivity, whereas delayed hypersensitivity would be shown by a response between 2 and 24 hours [27].  
Highly purified and recombinant insulin preparations are virtually free of protein contaminants, an advantage that has undoubtedly 
contributed to the decreasing prevalence of insulin allergies. Currently, allergic reactions to insulin preparations are induced not only by the 
insulin molecule, especially when the tertiary structure of insulin is altered, but also by the presence of non-protein contaminants, or 
pharmaceutical additives, such as protamine sulphate, zinc or metacresol [12, 29]. Allergic reactions to protamine sulphate are common and 
should not be ignored. They can be easily detected with positive intradermal skin test reactions to protamine sulphate [26, 30] and they can 
be managed by switching NPH insulin preparations to other lente insulin preparations free of protamine. Finally, insulin-injection-site 
reactions associated with type 1 latex allergy have also been reported in exceptional cases with type 1 diabetes [31-33]. 
Local skin reactions are usually short-lived and resolve spontaneously within a few weeks despite continuation of insulin [14]. A 
standardized investigative procedure of suspected insulin preparation allergy was associated with relief of symptoms in > 90 % in a 
retrospective series of  22 cases [26]. If the skin reactions persist longer than several weeks, a number of potential options may be 
considered, including changing insulin to a less allogenic type (i.e. insulin analogues) and /or varying the insulin delivery mode (i.e. CSII). 
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These new options challenge the classical approach using desensitization procedure, a tolerance induction technique has been described to 
be successful in some cases, but is rather fastidious to implement in clinical practice [13,15,25,26].  
 
   2. CSII AND INSULIN ALLERGY 
CSII raises the important issue of stability of insulin within the delivery system [16], because of prolonged contact with plastic 
reservoirs and tubing, higher-temperature exposure, and possible agitation as described in presence of a constant pumping motion [34]. 
Possible interaction between plastic catheter tubings and regular insulin preparations used for CSII (35) and problem of insulin 
compatibility with polymer materials used in external pump infusion systems [36] have also pointed out. Despite potential changes in the 
tertiary structure of insulin, no increase in the incidence of allergic reactions to insulin was described in CSII-treated patients. Only contact 
dermatitis has been reported in some diabetic patients resulting from the presence of acrylates, epoxy resin, components of glue or nickel 
needle in the insulin pump infusion sets [37].  
CSII has been proposed to reduce allergy to insulin when injected conventionally [20]. Indeed, most desensitisation protocols involve 
the frequent administration of small and incrementally increasing doses of insulin in order to obtain low constant blood levels that gradually 
increase to therapeutic levels. Continuous delivery may be used to avoid repeated injections, and thus CSII would be an ideal method of 
desensitisation. Furthermore, if necessary, dermal hypersensitivity to insulin may be improved by simultaneous infusion of small amounts 
of corticosteroids with insulin in patients experiencing these reactions [38].  
The successful treatment with an insulin pump delivering regular insulin was first reported in a young girl with type 1 diabetes who, 
within two months of insulin therapy, developed generalised allergy due to both zinc and protamine in insulin preparation [39]. The first 
report of management of true insulin allergy using CSII was published in 1988 [40]. Three years after beginning insulin therapy with beef-
pork insulin, a 34-yr-old, nonatopic woman developed urticaria. Laboratory findings excluded the usual etiologies of generalized urticaria 
and/or pruritus, but specific IgE antibodies against bovine and porcine insulins were found. Antihistaminic treatment and desensitisation 
with high-purified porcine and human insulin were attempted without improvement. Therefore, CSII with human regular insulin was 
started. With this therapeutic regimen a rapid improvement of subjective symptomatology was observed with the gradual disappearance of 
allergic reactions over 2 months. Interestingly, local allergic reactions in injection sites recurred one year later, when the patient again 
underwent conventional insulin therapy. Presence of specific IgE against porcine, bovine and human insulins was confirmed. The patient 
was again treated with CSII with a rapid disappearance of allergic reactions. This therapeutic attempt was based on the supposition that the 
infusion of insulin microdoses at a continuous basal rate could represent an effective desensitisation method. One proposed mechanism was 
that CSII is able to maintain the mast cells chronically degranulated in insulin-infusion areas and so block the immunological reaction liable 
to allergic manifestations [40]. 
Despite this initial favourable report, the use of CSII delivering human regular insulin in diabetic patients with insulin allergy when 
treated with conventional injection therapy remained exceptional, as only one single case has been described with continuous delivery of 
human insulin [41]. A 63-year-old insulin-dependent diabetic woman was hospitalised with itchy skin wheals at the injection sites of 
 5
human insulin. After intradermal skin testing was performed, the erythema and wheal were recorded immediately, and the increased titer of 
human insulin-specific IgE antibody indicated immediate-type allergy against human insulin. Administration of an anti-allergic drug or 
desensitisation for human insulin every two hours was not effective. In contrast, after CSII therapy was performed, both itching and wheal 
disappeared. The authors concluded that the process may be a desensitisation through CSII and suggested that CSII may be useful in the 
treatment for human insulin allergy [41].  
Several recent reports further confirmed the potential interest of CSII in the treatment of insulin allergy, but all concerned patients 
treated with pump delivering short-acting insulin analogues (vide infra). 
 
3. Insulin analogues and insulin allergy 
To develop insulin analogues with more desirable pharmacokinetic properties, alterations have been made in the amino acid sequence 
of human insulin. The human insulin analogues lispro and aspart are produced by interchange of the positions of the amino acids B28-Pro 
and B29-Lys, and replacing B28-Pro with Asp, respectively. These changes cause rapid dissociation of hexamers into monomers 
spontaneously, resulting in rapid absorption, action, and degradation of insulin [5,6]. Ideally, insulin analogues should neither produce an 
immune response that results in local or systemic allergic manifestations in excess of those of human insulin preparations nor generate 
antibodies that bind to and neutralize insulin. However, insulin analogues  may present new epitopes for recognition by the immune system. 
Interestingly, in vitro data suggested that insulin aggregates rather than native monomers cause cutaneous allergy and that antigenicity of 
insulin preparations correlates with the relative concentration of aggregates [16]. Structural changes leading to insulin lispro and insulin 
aspart (monomeric insulins) were initially reported to result in decreased immunogenicity in in vivo studies [17,18]. However, recent 
studies with both insulin lispro [42,43] or insulin aspart [44] rather reported results supporting similar immunogenicity of the two analogues 
when compared to human regular insulin. A multinational, multicentre combination of controlled and non-controlled, open-label studies of 
4.5 years’ duration showed that the incidence of insulin allergy in patients receiving subcutaneous administration of insulin lispro was not 
different from that in patients treated with recombinant regular human insulin [42]. Lindholm et al [44] reported that insulin aspart caused 
allergic reactions as frequently as regular human insulin, although there was no consistent relationship between antibody formation and 
adverse events.  
Nevertheless, insulin lispro or insulin aspart analogues may be less antigenic for people with insulin allergy as they do not aggregate 
to form polymers [16]. Anecdotal reports suggested local and generalized  allergy  to human insulin could be successfully treated  with 
insulin lispro [45-49] or with insulin aspart [49-51]. In the series of 22 cases published by Bodtger et al [26], 5 patients were treated with 
insulin analogues, among whom 3 with a clear success and 2 with partial improvement. Successful treatment of insulin allergy in a 1-year-
old infant with neonatal diabetes by lispro and glargine insulin was reported recently [52]. However, insulin allergy has also been reported 
with insulin lispro [53-55] and with insulin aspart [19,56]. One case of insulin allergy to insulin aspart, associated with insulin resistance, 
occurred in a patient with lung cancer and was considered as a paraneoplastic syndrome based on interleukin-6 secretion [56]. In a recent 
review of the literature focusing on systematic allergy to insulin, a series of 11 cases of lispro or aspart sensitization were reported, 
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demonstrating that clinical allergy to these new insulin analogues exists as well [57].  Insulin allergy was not always treated successfully 
with insulin aspart [55,58]. Interestingly, one case report described the positive effect of using a short-acting insulin analogue instead of 
crystalline insulin in a patient already on CSII therapy [59]. This 22-year–old woman with type 1 diabetes developed pruritus and erythema 
at the injection site three months after starting treatment with crystalline insulin given through an infusion pump. Following various 
attempts of desensitisation, the short-acting insulin analogue lispro was used. It was first administered to increasing doses using classical 
subcutaneous injections. Urticaria disappeared within three days, and insulin lispro could be administered by pump infusion with no 
recurrence of urticaria over a follow-up of more than 18 months. The favourable course of this severe insulin allergy emphasizes the 
potential interest of insulin lispro in patients with insulin allergy, and opens new prospects in combining CSII and short-acting insulin 
analogues. 
 New long-acting insulin analogues such as insulin glargine and insulin detemir offer the potential advantage of a better basal 
insulin coverage over a 24-h period as compared to insulin NPH, with less hypoglycaemic events [5,6]. Therefore, once-daily dose of 
insulin glargine has been proposed as an alternative to CSII as it provides more effective glycaemic control over 24 hours as compared to 
intermediate insulin NPH [21,22]. Two case reports [52,60] showed that insulin glargine can resolve a generalized allergy to human insulin 
in type 1 diabetic patients. The first case was a 45-year-old type 1 diabetic Japanese man with generalized allergy to human insulin who 
was successfully treated with insulin glargine [60]. Although the precise mechanism to induce the tolerance across other insulins remains 
unclear, this is the first report to demonstrate that insulin glargine allows generalized insulin allergy to be overcome. The other case 
concerns a 1-year-old infant with neonatal diabetes [52]. In this infant, intradermal tests confirmed the insulin allergy to different kinds of 
insulin and attempts of treatment with antiallergic drugs and gradual insulin desensitization with low doses of regular insulin were not 
successful.  As skin tests were negative with glargine insulin, treatment with this new basal insulin was initiated without any allergic 
reaction and an adequate glycaemic control over a 6-month period. However, glargine insulin can not always be considered as an 
alternative in insulin allergy. Indeed, the first report of allergy with glargine insulin has been described in an 81-year-old man with type 2 
diabetes [61]. In that particular case, skin-prick tests were positive for human and porcine insulin as well as for lispro and glargine insulin, 
but not for aspart insulin. Therefore, the patient was treated successfully with CSII of aspart with no local reaction and gradually improved 
metabolic control. Another preliminary report described the case of a 20-year-old diabetic woman, who presented delayed local 
manifestations after glargine injection, with negative intradermal reaction to all insulin preparations tested, except for a weak response for 
glargine [62]. A 60-year type 2 diabetic patient with allergy reactions to all kinds of human insulin and short-acting insulin analogues, 
showed similar cutaneous reactions to glargine as to other insulin preparations  [63]. Finally, Castera et al [57] described a case of allergy to 
all kinds of insulin commercially available in France at that time, lispro, aspart and glargine insulin included. However, they did not test the 
new rapid analogue glulisine and the new long acting analogue detemir. Almost no information is available in literature concerning the 
allergenicity of these new insulin analogues or their use in the treatment of insulin allergy. Nevertheless, a first case of type III allergy to 
the new long-acting insulin analogue detemir has been recently reported in a 31-year old man with type 1 diabetes for 20 years without any 
history of allergy, especially to previous insulin preparations, including insulin glargine and insulin aspart [64]. Thus, contradictory 
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observations are available in the literature regarding the potential interest or the absence of deleterious effect of the new long-acting insulin 
analogues glargine and detemir as far as insulin allergy is concerned. 
 
4. CSII with insulin analogues and insulin allergy 
As CSII with regular insulin has proven its efficacy to treat insulin allergy and as the use of insulin analogues could also reduce 
insulin allergy, one may expect that the combination of short-acting insulin analogue and CSII should be the best way to manage patients 
with insulin allergy [20]. One study demonstrated that potency and purity of insulin lispro were practically unchanged after 2 days of 
pumping in two different insulin infusion systems when syringes and catheters are replaced at 48-h intervals [65]. A recent study confirmed 
appropriate physiochemical stability of insulin lispro for use in various pump devices [66]. 
Ten case reports have been recently published demonstrating the efficacy of CSII delivering short-acting insulin analogues (8 with 
insulin lispro, 2 with insulin aspart) in patients with various types of diabetes presenting local cutaneous insulin reactions with conventional 
insulin treatment. They concerned various types of diabetic patients, i.e. a child with type 1 diabetes, two elderly patient with insulin-
requiring type 2 diabetes, two middle-age patients with type 2 diabetes, four adults with type 1 diabetes of various duration and a woman 
with gestational diabetes. These ten cases that illustrate successful desensitisation using CSII delivering insulin lispro or insulin aspart will 
be briefly described (Table 1). Such detailed description of individual cases will allow emphasize the heterogeneity of demographic 
characteristics, clinical presentation, type of insulin responsible of allergy and attempts of management before trying CSII and short-acting 
insulin analogue.  
In a 5-year-old girl with type 1 diabetes and insulin allergy, successful desensitisation could be obtained using an insulin pump and 
insulin lispro whereas additional oral antihistamine and co-administration of subcutaneous dexamethasone along with human insulin 
previously failed to control her symptoms [67]. In a 79-year-old man with a 28-year history of type 2 diabetes, the allergic reactions 
appeared to be variable in size and duration [68]. Three months after starting CSII with insulin lispro there has been no sign of an allergic 
response with successful reduction in HbA1c levels. In a 43-year-old-man with a 3-year history of type 1 diabetes, a treatment with CSII 
using insulin lispro was initiated to achieve insulin tolerance because of the increase in the intensity of the local reaction, despite 
antihistaminic therapy [69]. The allergic reaction immediately disappeared and optimal metabolic control was achieved.  In a 31-year-old 
pregnant woman with gestational diabetes, an allergy to insulin was suspected because of local reactions and confirmed by skin-prick tests 
[70]. A treatment with CSII and insulin lispro was initiated with an oral antihistaminic drug without local reaction. However, seven weeks 
after the initiation of such treatment, local reactions reappeared.  In a 21 year old woman, uncontrolled type 1 diabetes was observed due to 
severe cutaneous allergies to insulin resulting in poor compliance to intermittent insulin injections [71]. CSII using insulin lispro was 
initiated as a low-dose provider for both desensitisation and treatment of diabetes. Boluses were replaced with temporarily increased basal 
rates over 3 hours starting 1 h before meals. No local reaction at the insertion site of the catheter or elsewhere was observed anymore and 
the metabolic control progressively improved. One year later, although intradermal tests remained positive, antihistamine treatment could 
be stopped and premeal boluses were introduced without reactivating cutaneous allergies. In a 55-year-old woman with type 1 diabetes, an 
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allergy to insulin was diagnosed after 6 months of treatment with human insulin. This allergy was confirmed by intradermo-reaction tests 
for all kinds of insulin, except lispro. A treatment with CSII and insulin lispro was initiated and continued with a good tolerance and a good 
metabolic control [72]. In an 81-year-old type 2 diabetic patient, hypersensitivity to insulin was described consisting of local skin reaction 
followed by general urticarian lesions. The skin-prick tests were positive for human and porcine insulin forms and not for insulin aspart. 
Therefore, a treatment with CSII and insulin aspart was initiated and gave good results on the skin reactions and the metabolic control [61]. 
In a 25-year-old type 1 diabetic patient, after an initial diagnosis of protamine allergy, an allergy for all kinds of insulin (human, short- and 
long-acting analogues) was confirmed. A treatment with CSII and insulin aspart associated with oral corticoid therapy was used with 
success as a desensitisation method [73]. In a 50-year-old type 2 diabetic patient, allergic reactions presented at the local injection site. 
Intradermal tests confirmed the allergy all kinds of insulin  A desensitisation with CSII and insulin lispro was conducted with a real success 
[57]. In a 60-year-old uncontrolled type 2 diabetic patient, local skin reactions with feeling uncomfortable, sweaty and feverish were 
observed after all human insulin preparations, including insulin analogues aspart, lispro and glargine. He was commenced on an insulin 




 Local hypersensitivity to insulin and lipodystrophies associated with subcutaneous insulin therapy have become rare complications since 
the generalized use of human insulin Numerous recent observations, mainly published as short case reports, letters to the editor or abstracts, 
described the positive impact on these complications of using either CSII or short-acting insulin analogues, although controversial data 
were reported with the latter. Extensive analysis of the literature reveals that combining CSII and the use of a short-acting insulin analogue 
has been shown to be a valuable strategy in the treatment of localised and generalised hypersensitivity reactions in diabetic patients with 
insulin allergy.  
 9
   
REFERENCES 
 
1. Pickup J, Keen H. Continuous subcutaneous insulin infusion at 25 years : evidence base for the expanding use of insulin pump therapy in 
type 1 diabetes. Diabetes Care 2002; 25: 593-598.  
2. Weissberg-Benchell J, Antisdel-Lomaglio J, Seshadri R. Insulin pump therapy : a meta-analysis. Diabetes Care 2003; 26: 1079-1087.  
3. Colquitt J, Toyle P, Waugh N. Are analogues insulins better than soluble in continuous subcutaneous insulin infusion? Results of a meta-
analysis. Diabetic Med. 2003; 20: 863-866. 
4. Radermecker RP, Scheen AJ. Continuous subcutaneous insulin infusion with short-acting insulin analogues or human regular insulin : 
efficacy, safety, quality of life, and cost-effectiveness. Diabetes/Metab Res Rev. 2004; 20: 178-188. 
5. Hirsch IB. Insulin analogues. New Engl J Med. 2005; 352: 174-183. 
6. Oiknine R, Bernbaum M, Mooradian AD. A critical appraisal of the role of insulin analogues in the management of diabetes mellitus. 
Drugs 2005; 65: 325-340. 
7. Lawrence RD. Local insulin reactions. Lancet 1925; 1: 1125-1126. 
8. Vialettes B. L’allergie à l’insuline. Diabete Metab. 1986; 12 : 169-172. 
9. Schernthaner G. Immunogenicity and allergenic potential of animal and human insulins. Diabetes Care 1993; 16 (Suppl 3): 155-165. 
10. Paley RG, Tunbridge RE. Dermal reactions to insulin therapy. Diabetes 1952; 1: 22-27. 
11. Arkins JA, Engoring NH, Lennon E. The incidence of skin reactivity to insulin in diabetic patients. J Allergy 1962; 33: 69-72. 
12. Patterson R, Roberts M, Grammer LC. Insulin allergy; re-evaluation after two decades. Ann Allergy 1990; 64: 459-462. 
13. Grammer LC. Immunologic reaction to insulin and other proteins. Immunol Allergy Clin North Am. 1998; 18: 809-816. 
14. Richardson T, Kerr D. Skin-related complications of insulin therapy. Epidemiology and emerging management strategies. Am J Clin 
Dermatol. 2003; 4: 661-667. 
15. Sola-Gazagnes A, Pecquet C. Allergie à l’insuline en 2003. Journées de Diabétologie de l’Hôtel Dieu, Flammarion Médecine-Sciences, 
Paris, 2004, 161-179. 
16. Ratner RE, Phillips TM, Steiner M. Persistent cutaneous insulin allergy resulting from high-molecular-weight insulin aggregates. 
Diabetes 1990; 39: 728-833. 
17. Brange J, Owens DR, Kang S, Volund A. Monomeric insulins and their experimental and clinical implications. Diabetes Care 1990; 13: 
923-954. 
18. Ottesen JL, Nilsson P, Jami J, et al. The potential immunogenicity of human insulin and insulin analogues evaluated in a transgene mouse 
model. Diabetologia 1994; 37: 1178-1185. 
19. JiXiong X, Jianying L, Yulan C, Huixian C. The human insulin analog aspart can induce insulin allergy. Diabetes Care 2004; 27: 2084-
2085. 
 10
20. Radermecker RP, Scheen AJ. Treatment of allergy to insulin using continuous subcutaneous insulin infusion with short-acting insulin 
analogues. Infusystems International 2004, 3: 1-5. 
21. Lepore M, Pampanelli S, Fanelli C, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin 
analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000; 49: 2142-
2148. 
22. Doyle EA, Weinzimer SA, Steffen AT, et al. A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin 
infusion with multiple daily injections using insulin glargine. Diabetes Care 2004; 27: 1554-1558. 
23. Kahn CR, Rosenthal AS. Immunologic reactions to insulin: insulin allergy, insulin resistance, and the autoimmune insulin syndrome. 
Diabetes Care 1979; 2: 283-295. 
24. Grammer L. Insulin allergy. Clin Rev Allergy 1986; 4: 189-200. 
25. Messaad D, Outtas O, Demoly P. Hypersensibilité aux insulines. Presse Med. 2004; 33 : 631-638. 
26. Bodtger U, Wittrup M. A rational clinical approach to suspected insulin allergy: status after five years and 22 cases. Diabet Med. 2005; 
22: 102-106. 
27. De Shazo RD, Boehm TM, Kumar D, Galloway JA. Dermal hypersensitivity reactions to insulin: correlations of three patterns to their 
histopathology. J Allergy Clin Immunol. 1982; 69: 229-237. 
28. Silva MER, Mendes MJM, Ursich MJM, et al. Human insulin allergy-immediate and late type III reactions in a long-standing IDDM 
patient. Diabetes Res Clin Pract. 1997; 36: 67-70. 
29. Katahira M, Hara I, Nishizaki T. Insulin allergy decreased by Humulin S (Humulin R) and not by insulin aspart or Actrapid Penfill 
(Penfill R). Diabetic Med. 2005; 22: 1454-1459. 
30. Lee A-Y, Chey W-Y, Choi J, Jeon J-S. Insulin-induced drug eruptions and reliability of skin tests. Acta Derm Venereol. 2002; 82: 114-
117. 
31. Primeau M-N, Adkinson NF Jr, Hamilton RG. Natural rubber pharmaceutical vial closures release latex allergens that produce skin 
reactions. J Allergy Clin Immunol. 2001; 107: 958-962. 
32. Shojaei AR, Haas DA. Local anesthetic cartridges and latex allergy : a literature review. J Can Dent Assoc. 2002; 68: 622-626. 
33. Roest MA, Shaw S, Orton DI. Insulin-injection-site reactions associated with type 1 latex allergy. N Engl J Med. 2003; 348: 265-266. 
34. Lougheed W, Albisser AM, Martindale HM, Chow JC, Clement JR. Physical stability of insulin formulations. Diabetes 1983; 32: 424-
432. 
35. Chantelau E, Lange G, Gasthaus M, Boxberger M, Berger M. Interaction between plastic catheter tubings and regular insulin preparations 
used for continuous subcutaneous insulin-infusion therapy. Diabetes Care 1987; 10: 348-351. 
36. Melberg SG, Havelund S, Villumsen J, Brange J. Insulin compatibility with polymer materials used in external pump infusion systems. 
Diabet Med 1988; 5: 243-247. 
 11
37. Radermecker RP, Piérard GE, Scheen AJ. Lipodystrophy reactions to insulin : effects of continuous insulin infusion and new insulin 
analogues. Submitted. 
38. Grant W, deShazo RD, Frentz J. Use of low-dose continuous corticosteroid infusion to facilitate insulin pump use in local insulin 
hypersensitivity. Diabetes Care 1986; 9: 318-319. 
39. Gin H, Aubertin J. Generalized allergy due to zinc and protamine in insulin preparation treated with insulin pump. Diabetes Care 1987; 
10: 789-790. 
40. Valentini U, Cimino A, Rocca L, Pelizzari R, Rotondi A, Tosoni C. CSII in management of insulin allergy. Diabetes Care 1988; 11: 97-
8. 
41. Nagai T, Nagai Y, Tomizawa T, Mori M. Immediate-type human insulin allergy successfully treated by continuous subcutaneous insulin 
infusion. Intern Med. 1997; 36: 575-578. 
42. Fineberg NS, Fineberg SG, Anderson JH, Birkett MA, Gibson RG, Hufferd S. Immunologic effects of insulin lispro [(Lys (B28), Pro 
(B29) human insulin)] in IDDM and NIDDM patients previously treated with insulin. Diabetes 1996; 45: 1750-1754. 
43. Fineberg SE, Huang J, Brunelle R, Gulliya KS, Anderson JH Jr. Effect of long-term exposure to insulin lispro on the induction  of 
antibody response in patients with type 1 or type 2 diabetes. Diabetes Care 2003; 26: 89-96. 
44. Lindholm A, Jensen LB, Home PD, Raskin P, Boehm BO, Rastam J. Immune responses to insulin aspart and biphasic insulin aspart in 
people with type 1 and type 2 diabetes. Diabetes Care 2002; 25: 876-882. 
45. Kumar D. Lispro analog for treatment of generalized allergy to human insulin. Diabetes Care 1997; 20: 1357-1359. 
46. Abraham MR, Al-Sharafi BA, Saavedra GA, Khardori R. Lispro in the treatment of insulin allergy. Diabetes Care 1999; 22: 1916-1917. 
47. Lluch-Bernal M, Fernandez M, Herrera-Pombo JL, Sastre J. Insulin lispro, an alternative in insulin hypersensitivity. Allergy 1999; 54: 
186-187. 
48. Panczei P, Hosszufalusi N, Horvath MM, Horvath A. Advantage of insulin lispro in suspected insulin allergy. Allergy 2000; 55: 418-9. 
49. Adachi A, Fukunaga A, Horikawa T. A case of human insulin allergy induced by short-acting and intermediate-acting insulin but not by 
long-acting insulin. Int J Dermatol. 2004; 43: 597-599. 
50. Airaghi L, Lorini M, Tedeschi A. The insulin analog aspart : a safe alternative in insulin allergy. Diabetes Care 2001; 24: 2000. 
51. Yasuda H, Nagata M, Moriyama H, et al. Human insulin analog insulin aspart does not cause insulin allergy. Diabetes Care 2001; 24: 
2008-2009. 
52. Kara C, Kutlu AO, Evliyaoglu O, Bilgili H, Yildirim N. Successful treatment of insulin allergy in a 1-year-old infant with neonatal 
diabetes by lispro and glargine insulin. Diabetes Care 2005; 28: 983-984. 
53. Hermoso F, Vazquez M, Chaves G, Reviriego J, Andion R. Generalized allergy to human insulin treated with insulin lispro (Abstract). 
Diabetologia 1997; 40 (Suppl 1): A349. 
54. Barranco R, Herrero T, Tomero P, et al. Systemic allergic reaction by a human insulin analog. Allergy 2003; 58: 536. 
 12
55.  Yokoyama H, Fukumoto S, Koyama H, Emoto M, Kitagawa Y, Nishizawa Y. Insulin allergy; desensitization with crystalline zinc-
insulin and steroid tapering. Diab Res Clin Pract. 2003; 61: 161-166. 
56. Mizuhashi S, Nakamura K, Mori Y, Noda M, Nakanishi K. Insulin allergy and immunologic insulin resistance caused by interleukin-6 in 
a patient with lung cancer. Diabetes Care 2006; 29: 1711-1712. 
57. Castera  V, Dutour-Meyer A, Koeppel M, Petijean C, Darmon P. Systemic allergy to human insulin and its rapid and long acting analogs : 
successful treatment by continuous subcutaneous insulin lispro infusion. Diabetes Metab. 2005; 31: 391-400. 
58. Takata H, Kumon Y, Osaki F, et al. The human insulin analogue aspart is not the almighty solution for insulin allergy. Diabetes Care 
2003; 26: 253-254. 
59. Frigerio C, Aubry M, Gomez F, et al. Desensitization-resistant insulin allergy. Allergy 1997; 52: 238-239. 
60. Moriyama H, Nagata M, Fujihira K, et al. Treatment with human analog (GlyA21, ArgB31,ArgB32) insulin glargine (HOE901) resolves a 
generalized allergy to human insulin in type 1 diabetes. Diabetes Care 2001; 24: 411-412. 
61. Durand-Gonzalez KN, Guillausseau N, Pecquet C, Gayno JP. Glargine insulin is not an alternative in insulin allergy. Diabetes Care 2003; 
26: 2216. 
62. Vernassière C, Tréchot P, Guerci B, Commun N, Schmutz JL, Barbaud A. Deux premiers cas de sensibilisation retardée aux insulines 
humaines recombinantes modifiées (Abstract). Ann Dermatol Venereol. 2004; 13: P1. 
63. Moyes V, Driver R, Croom A, Mirakian R, Chowdhury TA. Insulin allergy in a patient with Type 2 diabetes successfully treated with 
continuous subcutaneous insulin infusion. Diabet Med. 2006; 23: 204-206. 
64. Darmon P, Castera V, Koeppel M-C, Petitjean C, Dutour A. Type III allergy to insulin detemir. Diabetes Care 2005; 28: 2980. 
65. Lougheed WD, Zinman B, Strack TR, et al. Stability of insulin Lispro in insulin infusion systems. Diabetes Care 1997; 20: 1061-1065. 
66. Defelippis  MR, Bell MA, Heyob JA, Storms SM. In vitro stability of insulin lispro in continuous subcutaneous insulin infusion. Diabetes 
Technol Ther. 2006; 8: 358-368.  
67. Eapen SS, Connor EL, Gern JE. Insulin desensitisation with insulin lispro and an insulin pump in a 5-year-old child. Ann Allergy Asthma 
Immunol. 2000; 85: 395-397. 
68. Pratt EJ, Miles P, Kerr D. Localized insulin allergy treated with continuous subcutaneous insulin. Diabetic Med 2001; 18: 514-516. 
69. Näf S, Esmatjes E, Recasens  M, et al. Continuous subcutaneous insulin infusion to resolve an allergy to human insulin. Diabetes Care 
2002; 25: 634-635. 
70. Durand-Gonzalez KN, Guillausseau N, Anciaux ML, Hentschel V, Gayno JP. Allergy to insulin in a woman with gestational diabetes 
mellitus : transient efficiency of continuous subcutaneous insulin lispro infusion. Diabetes Metab. 2003; 29: 432-434. 
71. Sola-Gazagnes A, Pecquet C, Radermecker R, et al. Successful treatment of insulin allergy in a type 1 diabetic patient by means of 
constant subcutaneous pump infusion of insulin. Diabetes Care 2003; 26: 2961-2962. 
72. Imiela A, Tavernier J-Y, Carotte-Lefebvre I, Deverny F, Delaporte E, Lamblin C. Allergie à l’insuline humaine recombinante : à propos 
de 3 cas avec manifestations immédiates généralisées. Rev Franc All Immunol Clin. 2003; 43: 165-169. 
 13
73. Matheu V, Perez E, Hernandez M, et al. Insulin allergy and resistance successfully treated by desensitisation with Aspart insulin. Clin 
Mol Allergy 2005; 3: 16 doi:10.1186/1476-7961-3-16. 
 
Acknowledgements 
No sources of funding were used to assist in the preparation of this review. The authors have no conflicts of interest that are directly relevant to 
the content of this review. 
 
Figure 1 : Immunological reactions to insulin (adapted from reference 23). 
  
 
Table 1 : Brief description of ten clinical cases showing positive effects of continuous subcutaneous infusion (CSII) of a short-acting insulin 











RAST Skin tests Insulin used 
in pump 
Eapen et al 
2000 (67) 





Latex - NPH + 
Regular + 
Lispro 
Pratt et al 
2001 (68) 










Näf et al 
2002 (69) 










Gonzales et al 
2003 (70) 
31 Gestational 0.5 Human Local 
(Type I) 
















Imiela et al 
2003 (72) 
55 Type 1 72 Human Local 
Then systemic 
(Type I) 






Gonzales et al 
2003 (61) 
81 Type 2 <12 Human Local 
Then systemic 
(Type I) 




Matheu et al 
2005 (73) 














Castera et al 
2005 (57) 












Moyes et al 
2006 (63) 












RAST: Reactive Allergen Specific Test  0: not realised or not available  -: negative test   
 +: positive test 
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